Founded by dermatologists, Veradermics leverages its front-line clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. The company has cultivated a pipeline of diverse, first-in-class, therapeutics for highly prevalent dermatologic conditions seen in adults and children. Target indications include common warts (verruca vulgaris), alopecia areata, molluscum contagiosum, androgenetic alopecia (pattern hair loss), and atopic dermatitis. Veradermics’ lead product candidate, VDMN, offers a new, patient-friendly, injection-free approach for the treatment of common warts. Veradermics is led by an executive team of board-certified dermatologists supported by a board of directors comprised of recognized biopharmaceutical industry leaders.
Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.
Dermatologists Developing First-in-Class Drugs For Dermatology
Addressing Pervasive Treatment Challenges in Dermatology
Veradermics has cultivated a dermatology-focused pipeline of five novel product candidates for large-market conditions seen in adults and children that are overdue for new treatment approaches including common warts, molluscum contagiosum, alopecia areata, androgenetic alopecia (pattern hair loss), and atopic dermatitis.